Related Experiment Videos
Blonanserin transdermal patch for treating delirium: A case series
Mari Hemmi1, Takuma Yamaguchi1, Yuki Shigetsura1
1Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan.
PCN Reports : Psychiatry and Clinical Neurosciences
|May 13, 2026
Summary
The blonanserin (BNS) transdermal patch shows promise for treating delirium, especially when oral medication is difficult. This study found an 84.3% response rate with manageable side effects.
Area of Science:
- Neurology
- Psychiatry
- Pharmacology
Background:
- Antipsychotics are standard for delirium but have formulation limitations.
- Alternative delirium treatments are needed, particularly those improving adherence.
- The blonanserin (BNS) transdermal patch offers a potential alternative, but its efficacy in delirium is understudied.
Purpose of the Study:
- To evaluate the effectiveness and safety of the blonanserin (BNS) transdermal patch for delirium management.
- To explore the rationale for using BNS patches in a clinical setting.
- To assess adverse events associated with BNS patch use in delirium patients.
Main Methods:
- Retrospective case series of 51 delirium patients treated with BNS patches.
- Data collected from electronic medical records at Kyoto University Hospital (Jan 2020 - June 2022).
- Delirium diagnosis per DSM-5 criteria; effectiveness assessed by clinical judgment.
Main Results:
- Hyperactive and mixed delirium observed in 41.2% and 56.9% of patients, respectively.
- An overall therapeutic response rate of 84.3% was achieved with BNS patches.
- Primary reason for BNS patch use was difficulty with oral medication (60.8%); 29.4% experienced adverse events, all resolved upon discontinuation.
Conclusions:
- The BNS transdermal patch demonstrates potential as an effective delirium treatment, especially for patients with medication administration challenges.
- The study highlights the BNS patch as a viable option for improving treatment adherence in delirium.
- Further research is warranted due to the retrospective nature of this study; findings should be interpreted cautiously.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...